Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05267886 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Study acronym: DOREMI-2
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jan 2026 to Dec 2026v7
  2. Primary completion date: Jan 2025 to Jan 2026v6
  3. Study sites: 2 to 3v5
  4. Study sites: 1 to 2v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 28, 2022 to Mar 5, 2022
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.
Trial Details
NCT Number NCT05267886
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions
(from sponsor)		 Shock, Cardiogenic
Related terms Shock, Shock, Cardiogenic
Enrollment 346 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov